Overview

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pharmaxis

Collaborator:

Parexel